

بسم الله الرحمن الرحيم

﴿ اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ ﴾

صدق الله

العظيم

(سورة العلق الآية 1)

Dedication

I dedicate this research to

My magnificent father...
who gave me the power and support in
every steps in my life

My beloved mother.....
Who taught me how I could be
humane

My beloved brothers and sisters....

For their support and kindness

My lovely husband and
kid.....

The persons whom I love, respect and
appreciate.....

&

Every one from whom I learned...

Acknowledgment

- ◆ First of all, thanks to Almighty Allah who gave me the power for preparation and completion of this study.
- ◆ With a great deal of respect I would like to express my thanks to my supervisor Professor Sulieman Mohamed Elsanousi for his advice, enthusiasm, help and endless guide.
- ◆ My deep thanks are extended to my Co- Supervisor Professor Yousif Fadlalla Hamedelnil and Doctor Nahid Ahmed Gornas for their help and encouragement.
- ◆ This study is honored by the help of the National Center of Kidney Disease and Surgery.
- ◆ Finally, thanks to staff members of the Central laboratory for their help and support.

Abstract

This study was carried out in Khartoum State during the period from March 2013 to March 2014, to study phenotypic and genotypic characterization of bacterial pathogens in hemodialysis patients and their antibiotics susceptibility. Two hundred and one blood specimens for culture were collected from patients attended 17 Dialysis Units. The specimens were cultured on Thioglycollate broth which support the growth of anaerobes and aerobes and has been used in modified form for blood culture purposes. The obtained colonies were investigated using VITEK 2 Compact System for bacterial identification and susceptibility testing. During this study, 62 patients showed positive blood culture. Out of them 56 (90.3%) patients had Gram-positive bacterial infections and 6 (9.7%) patients had Gram-negative bacterial infections. *Staphylococcus epidermidis* was the most common microorganism associated with hemodialysis catheter-related bloodstream infection, it involved 35 of the 62 (56.5%) cases. Other prominent bacteria included six *Enterococcus faecalis* and six *Enterococcus faecium* (9.7%),

Staphylococcus aureus 4 (6.5%), *Pseudomonas aeruginosa* 3 (4.8%), *Staphylococcus vitulinus*, *Staphylococcus hominis*, *Staphylococcus simulans*, *Streptococcus uberis*, *Enterobacter cloacae*, *Serratia marcescens* and *Escherichia coli* (1.6% each). The antibiotic susceptibility results showed that only vancomycin, linezolid, tigecycline and nitrofurantoin were fully efficacious against Gram-positive isolates, they were highly resistant to benzylpenicillin (92.9%) and oxacillin (83.9%). While Gram-negative isolates were fully resistant (100%) to ampicillin, ampicillin/sulbactam, cefazolin and ceftiofuran. They were all susceptible to amikacin.

In attempting to identify of *Staphylococcus epidermidis*, *P. aeruginosa*, *Enterococcus faecalis*, *Enterococcus faecium* and *Staphylococcus aureus* strains at the DNA level, Polymerase chain reaction (PCR) was used based on specific primer for 16S rRNA gene. The results showed that PCR was found to be rapid and more sensitive and specific in identification.

The presence of class 1 and 2 integrons was tested by PCR using primers specific for the integron integrase genes *intl1* and *intl2*. Class 1 integrase Gene was present in all Gram-negative isolates (6) and in 48 of 56 Gram-positive isolates. The class 2 *intl1* gene was not found in this study. Most integrons were present in the multi-resistant isolates, indicating a general concordance between the presence of

integrons gene and antibiotic resistance, and that the integrons have played an important role in the dissemination of antimicrobial resistance in these species.

الخلاصة

أجريت هذه الدراسة في ولاية الخرطوم في الفترة ما بين مارس 2013 وحتى مارس 2014 لدراسة خواص الطراز المظهري والجيني للبكتريا المسقمة عند مرضي غسيل الدم وحساسيتها للمضادات الحيوية. جمعت 201 عينة من الدم من مرضي يترددون علي 17 مركز للاستشفاء الدموي. وتم تزرع عينات الدم في اوساط ثيوجليكوليت السائله التي تستخدم لتحفيز نمو البكتريا الهوائية واللاهوائية. تم تحديد نوع البكتريا الممرضة واختبار حساسيتها للمضادات . VITEK 2 Compact System الحيوية بواسطة جهاز

اظهرت هذه الدراسه ان 62 عينة زراعة دم ايجابية النمو البكتيري، 56 ((90.3% منهم موجب لصبغة جرام بينما 6 (9.7%) سالبه لصبغة جرام. اظهرت

الدراسة ان العنقوديه البشرويہ البيضاء هي الاكثر شيوعا بين البكتريا المسببه لالتهاب الدم الناتج عن التهاب قسطرة الاوعيه الدمويه التي تستخدم في عملية الاستصفاء الدموي وتمثل 35 من اصل 62 حاله، يليها 6(9.7%) من المكوره المعويه البرازيه و 6 (9.7%) من المكوره المعويه الاليويه و 4 (6.5%) من المكوره العنقوديه الذهبية، 3(4.8%) من الزائفة الزنجاريه وواحد من كل من المكوره العنقوديه فيتيولينيس و المكوره العنقوديه هومينيس والمكوره العنقوديه سميولنس و المكوره العقديه ابرائس والامعائيه المزرقه والسراتيه الزايه والاشريكيه القولونيه بنسبة (1.6%) لكل

عكست هذه الدراسة مقاومه البكتريا الموجهه لصبغة جرام للبنزاييل بنسلين (92.9%) و الاوكساسلين (83.9%)، بينما لا توجد مقاومه للفانكوميسين واللينزوليد والتيفيسايكلين والنيتروفيرانتوين وان البكتريا السالبه لصبغة جرام عالية المقاومه (100%) لكل من الامبسلين والامبسيلين سلباكتام والسيغازولين والسيفواكزتين. وعكست ايضا فعاليه المضاد الحيوي الاميكاسين علي كل انواع البكتريا المعزوله

قد اظهر (PCR) خلصت الدراسة الي ان استخدام تفاعل البلمره المتسلسل دقه و حساسيه عاليه في تحديد جنس ونوع البكتريا تحت الدراسة وهي العنقوديه البشرويہ البيضاء و الزائفة الزنجاريه و المكوره المعويه البرازيه و المكوره المعويه الاليويه و المكوره العنقوديه الذهبية في وجود البادئ (S rRNA) المتخصص لجين (16)

و فئة 1 (intI1) و integron integrase وايضا تم التحقق من وجود الجينات واطهرت الدراسة (PCR) بواسطة تفاعل البلمره المتسلسل (intI2) فئة 2 موجود في كل البكتريا السالبه لصبغة جرام بينما وجد في 48 intI1 ان جين لم يوجد في هذه intI2 من 56 من البكتريا الموجبة لصبغه جرام وان جين يلعب دورا هاما في انتشار intI1 الدراسة. توصلت الدراسة الي ان جين مقاومه البكتريا للمضادات الحيويه

Table of Contents

Page

Content

الآية

8

| | |
|----------------------|---|
| Dedication | 9 |
| Acknowledgment | 9 |
| Abstract (English) | 9 |
| Abstract (Arabic) | 9 |
| Table of Contents | 9 |
| List of Tables | 9 |
| List of Figures | 9 |
| List of Abbreviation | 9 |

Chapter One: Introduction

1. Introduction

1

2. Rationale

4

3. Objectives

5

3.1. General objective

5

3.2. Specific objectives

5

Chapter two: Literature Review

2. Literature Review

6

6

2.1. Chronic Kidney Disease (CKD)

2.2. Dialysis

6

2.2.1. Hemodialysis

| | |
|---|----|
| | 7 |
| 2.2.2. Vascular Access for hemodialysis | 7 |
| 2.2.3. Hemodialysis Protocol and Catheter Care | 8 |
| 2.2.4. Complications | 9 |
| 2.2.4.1. Catheter-Related Bacteremia (CRB) | 9 |
| 2.2.4.1.1. Definition | 9 |
| 2.2.4.1.2. Risk Factors | 9 |
| 2.2.4.1.3. Etiology | 10 |
| 2.2.4.1.3.1. <i>Staphylococcus aureus</i> | 11 |
| 2.2.4.1.3.2. <i>Staphylococcus epidermidis</i> | 11 |
| 2.2.4.1.3.3. <i>Staphylococcus vitulinus</i> | 12 |
| 2.2.4.1.3.4. <i>Staphylococcus hominis</i> | 13 |
| 2.2.4.1.3.5. <i>Staphylococcus simulans</i> | 13 |
| 2.2.4.1.3.6. <i>Streptococcus uberis</i> | 13 |
| 2.2.4.1.3.7. <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> | 13 |
| 2.2.4.1.3.8. <i>Enterobacter cloacae</i> | 14 |
| 2.2.4.1.3.9. <i>Serratia marcescens</i> | |

| | | | | |
|------------|--|--|---|-----------|
| | | | | 15 |
| | | | 2.2.4.1.3.10. <i>Escherichia coli</i> | |
| | | | | 16 |
| | | | 2.2.4.1.3.11. <i>Pseudomonas aeruginosa</i> | |
| | | | | 16 |
| | | | 2.2.4.1.4. Diagnosis | |
| | | | | 17 |
| | | | 2.2.4.1.4.1. Clinical | |
| | | | | 17 |
| | | | 2.2.4.1.4.2. Physical | |
| | | | | 17 |
| | | | 2.2.4.1.4.3. Bacteriology | |
| | | | | 18 |
| | | | 2.2.4.1.4.3.1. Collection of Blood Samples | |
| | | | | 18 |
| | | | 2.2.4.1.4.3.2. Culture of Blood Samples | |
| | | | | 18 |
| | | | 2.2.4.1.4.3.3. VITEK 2 Compact System | |
| | | | | 18 |
| | | | 2.2.4.1.4.3.3.1. Reagent Cards | |
| | | | | 19 |
| | | | 2.2.4.1.4.3.3.1.1. Identificaton Cards (ID) | |
| | | | | 19 |
| | | | 2.2.4.1.4.3.3.1.2. Antimicrobial Susceptibility Testing (AST) | |
| | | | | 19 |
| | | | | 19 |
| | | | 2.2.4.1.4.4. Molecular Study | |
| | | | | 20 |
| | | | 2.2.4.1.4.4.1. Integrons | |
| | | | | 20 |
| | | | 2.2.4.1.4.4.2. 16S rRNA gene | |
| 22 | | | | |
| 2.2.4.1.5. | | | | Treatment |

23

2.2.4.1.6. Epidemiology

23

2.2.4.1.7. Prevention

24

2.2.4.1.7.1. Gentamicin and Heparin Lock (GHL) Protocol

24

2.2.4.1.7.2. Core Interventions for CDC's Dialysis

25

Chapter Three: Materials and Methods

3.1. Study design

27

3.1.1. Type of Study

27

3.1.2. Study area

27

3.1.3. Inclusion criteria

27

3.1.4. Exclusion criteria

28

3.1.5. Data Collection

28

3.2. Collection of specimens

28

3.3. Inoculation of specimens

29

3.3.1. Culture Media

29

3.3.2. Dilution of the sample

29

3.3.3. Procedure of Inoculation of Blood Samples

| | |
|--|----|
| | 29 |
| 3.4. Examination of Bacterial Growth | 30 |
| 3.5 Subculturing a blood culture broth | 30 |
| 3.5 Identification and susceptibility testing | 31 |
| 3.5.1. Primary Identification | 31 |
| 3.5.1.1 Colonial Morphology | 31 |
| 3.5.1.2 Gram's Stain | 32 |
| 3.5.2. Suspension Preparation | 32 |
| 3.5.2.1 Identification cards (ID) | 32 |
| 3.5.2.1.1 The Gram- negative identification card | 33 |
| 3.5.2.1.2 The Gram- positive identification card | 33 |
| 3.5.2.2 Antimicrobial susceptibility testing (AST) cards | 34 |
| 3.5.2.2.1 AST-GP 67 card | 34 |
| 3.5.2.2.2 AST-GN 75 card | 35 |
| 3.5.3 Inoculation | 35 |
| 3.5.4 Card Sealing and Incubation | 35 |
| 3.5.5 Optical System | |

| | |
|--|----|
| | 36 |
| 3.5.6 Test Reactions | 36 |
| 3.5.7 Database Development | 36 |
| 3.5.8 Analytical Techniques | 36 |
| 3.5.9 Identification Levels | 37 |
| 3.5.10 Interpretation of results | 37 |
| 3.6 Molecular diagnosis | 38 |
| 3.6.1 Extraction of genomic DNA | 38 |
| 3.6.2 Application of Polymerase Chain Reaction | 39 |
| 3.7 Statistical Analysis | 41 |
| Chapter Four: Results | |
| 4. Results | 42 |
| 4.1. Status of Patients in Dialysis | 42 |
| 4.2. Phenotypic results | 43 |
| 4.3. Antibiotic Sensitivity | 43 |
| 4.4 Genomic DNA Isolation | 44 |
| Chapter Five: Discussion | |
| | 51 |

Chapter Six :Conclusion and Recommendation

6.1.Conclusion

54

6.2.Recommendation

55

References

56

Appendices

Appendix 1. VITEK 2 Compact System Instruments

64

Appendix 2. Polymerase Chain Reaction Instruments 66

Appendix 3. Questionnaire 67

Appendix 4. MICs of the 56 Gram positive isolates 68

Appendix 5. MICs of the 6 Gram negative isolates 69

List of Tables

| Page | Content |
|--|--|
| | Table (1). Primers used in this study |
| | 41 |
| Table (2). Distribution of patients in dialysis centers according to state | |
| 45 | |
| | Table (3). Prevalence of pathogens according to patient's age |
| | group |
| | 45 |
| Table (4). Association between patient's antibiotic status and growth | |
| pattern | 45 |
| | Table (5). Association between Type of catheter and growth pattern |
| | 46 |
| Table (6). Association between days of catheter and growth pattern | |
| | 46 |
| | Table (7). Bacterial isolates from 62 blood cultures. |
| | 46 |
| | Table (8). The presence of integrons in 62 bacterial isolates |

47
Table (9). Association between antimicrobial susceptibility and
integron carriage in 56 Gram positive clinical isolates

47

Table (10). PCR assay with primers targeted to the 16S rRNA gene for
isolates 48

List of Figures

| | Content |
|--|----------------|
| Page | |
| Fig 1: PCR amplification product of class 1 integron integrase genes in 54 of 62 clinical isolates | 48 |
| Fig 2: PCR amplification product of 16S rDNA which was specific for <i>Staphylococcus epidermidis</i> | 49 |

Fig 3: PCR amplification product of 16S rDNA which was specific for
E. faecium 49

Fig 4: PCR amplification product of 16S rDNA which was specific for
E. faecalis and *P. aeruginosa*

50

Fig 5: PCR amplification product of 16S rDNA which was specific for
Staphylococcus aureus

50

List of Abbreviations

| Abbreviation | Meaning |
|--------------|--------------------------------------|
| (pmp) | per million population |
| AMC | amino-methylcoumarin |
| AST | antimicrobial susceptibility testing |
| ATCC | American type culture collection |
| AV | Arteriovenous |
| AVFs | Arteriovenous fistulas |

| | | |
|-------|------|----------------------------------|
| | AVGs | Arteriovenous grafts |
| | BSIs | Bloodstream infections |
| CAB | | Catheter-associated bacteremia |
| CDC | | Centers for Disease Control and |
| | | Prevention |
| | CKD | Chronic kidney disease |
| | CKF | Chronic kidney failure |
| CoNS | | Coagulase-negative staphylococci |
| CRB | | Catheter-Related Bacteremia |
| CRBI | | Catheter-related bloodstream |
| | | infection |
| CVCs | | Central venous catheters |
| | DNA | Deoxyribonucleic acid |
| | DOQI | Dialysis Outcome Quality |
| | | Initiative |
| ESRD | | End-stage renal disease |
| FMCNA | | Fresenius Medical Care-North |
| | | America |
| | GFR | Glomerular filtration rate |
| GHL | | Gentamicin and heparin lock |
| | GN | Gram negative |
| | GP | Gram positive |
| HCRI | | Hemodialysis-catheter related |
| | | infections |
| | HD | Hemodialysis |
| | ID | Identificaton card |
| | | integrase |
| | MICs | minimum inhibitory |
| | | concentrations |
| | MU | methylumbelliferone |
| NHSN | | National Healthcare Safety |
| | | Network |
| PCR | | Polymerase Chain Reaction |
| | PCs | permanent access |
| | RI | Resistant integron |
| | SI | Superintegrons |

TCC
TDCs
UTIs
VRE

Tunneled central venous catheter
Tunneled dialysis catheters
Urinary tract infections
Vancomycin-resistant enterococci